Here are the 424B prospectus supplements from Tyra Biosciences, Inc. (TYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.
Tyra Biosciences, Inc. (TYRA) is conducting a primary offering of 9,079,000 shares of common stock and pre-funded warrants to purchase 9,078,529 shares, under its shelf registration. The common stock is priced at $22.03 per share and the pre-funded warrants at $22.029 each, with a $0.001 exercise price per underlying share.
Gross proceeds are approximately $400.0 million, with net proceeds to Tyra of about $373.9 million after underwriting discounts, commissions and expenses. Tyra plans to use the proceeds, together with existing cash and investments, to advance its “dabogratinib 3x3” development strategy in FGFR-related indications, support preclinical and discovery programs, and for working capital and general corporate purposes.
The offering creates immediate dilution: net tangible book value per share increases from $5.93 to $10.58, implying $11.45 per-share dilution to new investors. Pre-funded warrants are exercisable at any time, subject to a 4.99%–19.99% beneficial ownership cap, will not be listed, and are expected to have limited liquidity.
The issuer of common stock trading under the symbol TYRA is updating its existing at-the-market equity program. An amendment to the sales agreement with TD Securities (USA) LLC (TD Cowen) permits additional issuances of common stock, par value $0.0001 per share, under an at-the-market offering.
The original sales agreement and related prospectus covered up to a maximum aggregate offering price of $150,000,000, all of which has been sold. After giving effect to this prospectus supplement and the amended sales agreement, the issuer may offer and sell up to an aggregate offering price of $250,000,000 of common stock. The common stock is listed on the Nasdaq Global Select Market, where the last reported sale price was $32.04 per share on August 3, 2026.